A randomized double-blind trial of levamisole in the therapy of recurrent aphthous stomatitis

Cree, J. De; Verhaegen, H.; Cock, W. De; Verbruggen, Frank

doi:10.1016/0030-4220(78)90523-6

Cited by 19 publications

(22 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Levamisole Some randomized studies report a significant benefit from the use of levamisole while others suggest that it might not decrease the ulcer duration, number, size, or frequency. However, associated adverse effects (nausea, hyperosmia, dysgeusia, and agranulocytosis) discourage its use except in recalcitrant ulceration (184–192).…”

mentioning

confidence: 99%

Aphthous ulcerations

2002

View full text Add to dashboard Cite

Recurrent aphthous stomatitis (RAS) is a chronic condition, usually with a childhood or adolescent onset and with a tendency to diminish in frequency and severity with age. Most patients are otherwise healthy. The differential diagnosis for “aphthae” includes vesiculobullous diseases, granulomas, and even squamous cell carcinomas. The onset of aphthous‐like lesions in adults suggests the possibility of developing a more complex systemic disorder such as Behcet's syndrome or inflammatory bowel disease. Treatment includes correction of underlying diseases or predisposing causes, and the use of topical and systemic anti‐inflammatory agents or immunomodulating drugs.

show abstract

mentioning

confidence: 99%

Aphthous ulcerations

2002

View full text Add to dashboard Cite

show abstract

“…Preliminary studies show that levamisole might exert a favorable effect in other rheumatic diseases like Reiter's syndrome [39,96] and systemic lupus erythematosus [42,43], but controlled studies are still required to substantiate such findings. In 11 controlled studies with 397 patients with recurrent aphthous ulceration a statistically highly significant improvement was obtained with levamisole as compared to placebo treatment [27,28,68,115]. In 11 controlled studies with 397 patients with recurrent aphthous ulceration a statistically highly significant improvement was obtained with levamisole as compared to placebo treatment [27,28,68,115].…”

Section: Chronic Inflammatory Diseasesmentioning

confidence: 99%

Immunoregulation with levamisole

Symoens

Rosenthal²,

Brabander

et al. 1979

Springer Semin Immunopathol

View full text Add to dashboard Cite

“…Inconclusive results were obtained in some studies of levamisole in neurological disorders, such as multiple sclerosis, where levamisole could possibly playa stabilising role on disease progression [150]. In 11 controlled studies with 397 patients with recurrent aphthous ulceration a statistically highly significant improvement was obtained with levamisole as compared to placebo treatment [27,28,68,115]. According to some preliminary studies, Crohn's disease might also be treated successfully with levamisole as measured by clinical, biochemical, and immunological parameters [12,103].…”

Section: Chronic Inflammatory Diseasesmentioning

confidence: 99%